Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2-3
pubmed:dateCreated
2007-3-2
pubmed:abstractText
The dopamine D3 receptor is primarily localized within the mesocorticolimbic system, and may therefore have potential as a pharmacotherapeutic target for the treatment of drug dependence. Studies have shown that the selective dopamine D3 receptor antagonist SB-277011A reduces a variety of dependence-related behavioral effects of cocaine, alcohol and heroin. A previous study examining SB-277011A on nicotine self-administration using relatively low doses of the antagonist and a low response requirement for nicotine found no effect on drug-taking behavior per se, whereas reinstatement of nicotine-seeking was reduced. The purpose of the present study was to further examine the effects of higher doses of SB-277011A on nicotine self-administration in rats under a progressive-ratio (PR) schedule, which imposes relatively high response requirements for nicotine. Rats were trained to respond under a PR schedule of either nicotine or food reinforcement. Once responding was stable, SB-277011A (3-56 mg/kg) or vehicle was administered i.p. 1 h prior to the operant session. The highest dose tested significantly decreased the mean number of reinforcers and mean response rates in the nicotine self-administration group, but had no effect on either the mean number of reinforcers or response rate in the food group. In a separate set of experiments, the effects of SB-277011A on locomotor activity were measured. At the dose that significantly decreased nicotine self-administration, total distance traveled was also significantly decreased, suggesting that the effect on operant responding at the high dose of SB-277011A is at a threshold for motor effects and may not be directly mediated by an action at dopamine D3 receptors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
559
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
173-9
pubmed:dateRevised
2011-8-1
pubmed:meshHeading
pubmed-meshheading:17303116-Animals, pubmed-meshheading:17303116-Behavior, Animal, pubmed-meshheading:17303116-Conditioning, Operant, pubmed-meshheading:17303116-Dopamine Antagonists, pubmed-meshheading:17303116-Dose-Response Relationship, Drug, pubmed-meshheading:17303116-Eating, pubmed-meshheading:17303116-Infusions, Intravenous, pubmed-meshheading:17303116-Male, pubmed-meshheading:17303116-Motor Activity, pubmed-meshheading:17303116-Nicotine, pubmed-meshheading:17303116-Nicotinic Agonists, pubmed-meshheading:17303116-Nitriles, pubmed-meshheading:17303116-Rats, pubmed-meshheading:17303116-Rats, Long-Evans, pubmed-meshheading:17303116-Receptors, Dopamine D3, pubmed-meshheading:17303116-Reinforcement Schedule, pubmed-meshheading:17303116-Reward, pubmed-meshheading:17303116-Self Administration, pubmed-meshheading:17303116-Tetrahydroisoquinolines, pubmed-meshheading:17303116-Tobacco Use Disorder
pubmed:year
2007
pubmed:articleTitle
Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats.
pubmed:affiliation
Minneapolis Medical Research Foundation, 914 South 8th Street, Minneapolis, MN 55404, USA.
pubmed:publicationType
Journal Article